01—Abstract
Summary
Summary of the 10-Q filed August 7, 2026. Cited figures are marked; the original filing is the authoritative source.
Merck & Co., Inc. reported a net loss of $1.335 billiona for the second quarter of 2026, a significant shift from the $4.427 billion net income reported in the same period of the prior year.
This loss, equating to $0.54b per share, is largely attributable to substantial investments in research and development, particularly the significant charges related to the acquisitions of Terns Pharmaceuticals, Inc. ($5.7 billion) and Cidara Therapeutics, Inc. ($9.0 billion). Despite the quarterly loss, total sales showed a modest increase of 5% year-over-year to $16.6 billion, driven by strong performance in oncology, notably Keytruda, and the Animal Health segment. The company's strategic acquisitions aim to bolster its pipeline and future growth, but have created near-term pressure on profitability.
For the first six months of 2026, Merck reported a net loss of $5.575 billionc compared to a net income of $9.506 billion in the prior year. This widening loss is also heavily influenced by the substantial R&D expenses from acquisitions.
The balance sheet reflects a significant decrease in cash and cash equivalents, from $14.565 billion at the end of 2025 to $6.849 billiond at June 30, 2026, due in part to funding these acquisitions. While the company faces profitability headwinds in the short term due to these strategic investments, the continued growth in key pharmaceutical products and the Animal Health division signal underlying operational strength.
02—Key points
Key Highlights
- Merck reported a net loss of $1.335 billion for Q2 2026, a significant decline from $4.427 billion net income in Q2 2025, primarily due to large R&D expenses from acquisitions.
- Total sales increased by 5% year-over-year to $16.6 billion in Q2 2026, indicating continued top-line growth despite the net loss.
- Significant R&D expenses were incurred due to the acquisitions of Terns Pharmaceuticals ($6.8 billion, including $5.7 billion IPR&D charge) and Cidara Therapeutics ($9.2 billion, including $9.0 billion IPR&D charge) in 2026.
- Keytruda sales continued to grow, with combined sales of Keytruda/Keytruda Qlex increasing 5% in Q2 2026, driven by higher net pricing and increased demand, particularly in earlier-stage indications.
- The Animal Health segment demonstrated robust growth, with sales increasing 8% in Q2 2026, driven by both livestock and companion animal products.
- Cash and cash equivalents decreased substantially from $14.565 billion at the end of 2025 to $6.849 billion at June 30, 2026, reflecting cash outflows for acquisitions and other investments.
- The company is facing ongoing pricing pressures globally due to healthcare cost containment efforts and legislative actions like the Inflation Reduction Act (IRA), with certain key products like Januvia and Janumet selected for government price setting.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed August 7, 2026Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $16.61B$15.81B | +5.1% |
| Cost of Revenue | $4.39B$3.56B | +23.6% |
| Gross Profit | $12.21B$12.25B | −0.3% |
| R&D Expenses | $9.74B$4.05B | +140.6% |
| SG&A Expenses | $2.90B$2.65B | +9.6% |
| Net Income | -$1.33B$4.43B | −130.2% |
| EPS (Basic) | $-0.54$1.76 | −130.7% |
| EPS (Diluted) | $-0.54$1.76 | −130.7% |
| Shares Outstanding (Basic) | 2.47B2.51B | −1.6% |
| Shares Outstanding (Diluted) | 2.47B2.51B | −1.7% |
05—Questions
Frequently Asked Questions
What is the primary reason for Merck's net loss in the second quarter of 2026?
Merck reported a net loss of $1.335 billion in the second quarter of 2026 primarily due to significant research and development expenses stemming from substantial acquisitions. Specifically, the acquisitions of Terns Pharmaceuticals, Inc. and Cidara Therapeutics, Inc. resulted in substantial charges for acquired in-process research and development (IPR&D).
How did Merck's sales perform in the second quarter of 2026?
Merck's total sales increased by 5% year-over-year to $16.6 billion in the second quarter of 2026. This growth was driven by strong performance in the oncology franchise, particularly Keytruda, and continued momentum in the Animal Health segment.
What is the outlook for Keytruda sales?
Keytruda, along with Keytruda Qlex, continues to show growth, with combined sales up 5% in Q2 2026. The growth is attributed to higher net pricing, increased demand across various tumor types and earlier-stage indications, and ongoing regulatory approvals for new uses.
How has the company's cash position changed, and what is the impact of recent acquisitions?
Merck's cash and cash equivalents significantly decreased from $14.565 billion at the end of 2025 to $6.849 billion at June 30, 2026. This reduction is largely due to substantial cash outlays for strategic acquisitions, including Terns Pharmaceuticals and Cidara Therapeutics, as well as other investing activities.
What are the potential impacts of regulatory and pricing pressures on Merck's business?
Merck faces ongoing pricing pressures globally due to healthcare cost containment efforts. In the U.S., legislative actions like the Inflation Reduction Act are leading to government price setting for certain key products, including Januvia and Janumet, which will likely impact future revenue. International markets also continue to exert pricing pressure through government-mandated actions and cost-containment measures.
06—Continue